共 231 条
[11]
Fraitag S(2016)Cutaneous manifestations in patients with mastocytosis: consensus report of the European competence network on mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology J Allergy Clin Immunol 137 35-45
[12]
Canioni D(2012)Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal Int Arch Allergy Immunol 157 215-225
[13]
Billemont B(2011)Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options J Hematol Oncol 4 10-381
[14]
Suarez F(1994)Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO study group Osteoporos Int 4 368-1434
[15]
Lanternier F(2009)Histamine promotes osteoclastogenesis through the differential expression of histamine receptors on osteoclasts and osteoblasts Am J Pathol 174 1426-350
[16]
Lortholary O(2002)Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients Int Arch Allergy Immunol 128 344-6032
[17]
Hermine O(2003)Targeted deletion of histidine decarboxylase gene in mice increases bone formation and protects against ovariectomy-induced bone loss Proc Natl Acad Sci U S A 100 6027-778
[18]
Frances C(2011)Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis Am J Med 124 776-1328
[19]
Degboe Y(2007)Glucocorticoid-induced osteoporosis: pathophysiology and therapy Osteoporos Int 18 1319-685
[20]
Eischen M(2017)Bone mineral density and microarchitecture in patients with essential thrombocythemia and polycythemia vera Osteoporos Int 28 677-123